<DOC>
	<DOCNO>NCT00156884</DOCNO>
	<brief_summary>This study design determine whether combination low dose cisplatin strontium-89 show clinical promise symptomatic treatment bone metastases hormone refractory prostate cancer .</brief_summary>
	<brief_title>A Trial Strontium +/- Cisplatin Palliation Bone Pain Secondary Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description>This study design determine whether combination low dose cisplatin strontium-89 show clinical promise symptomatic treatment bone metastases hormone refractory prostate cancer .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>adenocarcinoma prostate life expectancy &gt; 3 month , symptomatic bone metastasis radiologic evidence metastatic bone disease stable level pain control &gt; 18 year ability complete assessment prior treatment ( chemo ) &gt; 4 week previous discontinue antiandrogens &gt; 4 week prior strontium therapy previous hemibody RT within 6 week previous cytotoxic chemotherapy within 4 week use bisphosphonate medication within 4 week change steroid dose within 4 week active uncontrolled infection impend present spinal cord compression significant neurological disorder impend pathological fracture severe urinary incontinence</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>cisplatin</keyword>
	<keyword>strontium-89</keyword>
	<keyword>phase II</keyword>
</DOC>